Advanced

Aspects of prophylactic treatment of hemophilia

Ljung, Rolf LU (2016) In Thrombosis Journal 14(S.1).
Abstract

Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in... (More)

Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Factor IX, Factor VIII, Hemophilia A, Hemophilia B, Prophylaxis
in
Thrombosis Journal
volume
14
issue
S.1
publisher
BioMed Central
external identifiers
  • scopus:84990041946
  • wos:000395268200014
ISSN
1477-9560
DOI
10.1186/s12959-016-0103-3
language
English
LU publication?
yes
id
0bd6f211-18cf-4bc6-9618-257e115bf42a
date added to LUP
2016-10-21 07:55:42
date last changed
2017-11-05 05:08:23
@article{0bd6f211-18cf-4bc6-9618-257e115bf42a,
  abstract     = {<p>Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.</p>},
  articleno    = {30},
  author       = {Ljung, Rolf},
  issn         = {1477-9560},
  keyword      = {Factor IX,Factor VIII,Hemophilia A,Hemophilia B,Prophylaxis},
  language     = {eng},
  month        = {10},
  number       = {S.1},
  publisher    = {BioMed Central},
  series       = {Thrombosis Journal},
  title        = {Aspects of prophylactic treatment of hemophilia},
  url          = {http://dx.doi.org/10.1186/s12959-016-0103-3},
  volume       = {14},
  year         = {2016},
}